Chadha Ranjit S
Known title: VP & Principal Accounting Off.CIK: 0001672529
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| ICFI | ▲ Buy | Option Exercise | 197 | $0 | 3/20/2026 | View on chart |
| ICFI | ▲ Buy | Option Exercise | 102 | $0 | 3/20/2026 | View on chart |
| ICFI | ▼ Sell | Tax Withholding | 37 | $2K | 3/20/2026 | View on chart |
| ICFI | ▼ Sell | Tax Withholding | 70 | $5K | 3/20/2026 | View on chart |
| ICFI | ▲ Buy | Option Exercise | 103 | $0 | 3/20/2025 | View on chart |
| ICFI | ▼ Sell | Tax Withholding | 37 | $3K | 3/20/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 8 | $0 | 7/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $0 | 4/8/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 127 | $7K | 3/4/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 1,173 | $0 | 3/4/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 3 | $0 | 1/14/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 3 | $168 | 10/8/2021 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 70 | $4K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ICF International reports Q2 2026 results and receives rating upgrade
ICF International released its second-quarter 2026 earnings, a standard periodic update for the company. Following the report, the stock received a rating upgrade to Buy, signaling a shift in analyst sentiment. This development is relevant as the average analyst target price sits at $107.25, well above the current trading range. The news highlights ongoing interest in the company's performance within the business services sector.
ICF International reports Q2 2026 results and receives rating upgrade. ICF International released its second-quarter 2026 earnings, a standard periodic update for the company. Following the report, the stock received a rating upgrade to Buy, signaling a shift in analyst sentiment. This development is relevant as the average analyst target price sits at $107.25, well above the current trading range. The news highlights ongoing interest in the company's performance within the business services sector.